Showing results (491-500 of 564) with videos related to
Sort By:
Pageof 57
Nature Communications|October 30, 2024
MLL oncoprotein levels influence leukemia lineage identitiesDerek H Janssens, Melodie Duran, Dominik J Otto, et al.Biorxiv : the Preprint Server for Biology|January 18, 2024
KMT2A oncoproteins induce epigenetic resistance to targeted therapiesDerek H Janssens, Melodie Duran, Dominik J Otto, et al.Micromachines|February 24, 2024
Using Compound Neural Action Potentials for Functional Validation of a High-Density Intraneural Interface: A Preliminary StudyAritra Kundu, Erin Patrick, Seth Currlin, et al.Journal of Gastroenterology|March 20, 2012
Excess weight among colorectal cancer survivors: target for interventionI Soerjomataram, M S Y Thong, I J Korfage, et al.Oncology|September 19, 2012
Cisplatin-docetaxel induction plus concurrent 3-D conformal radiotherapy and weekly chemotherapy for locally advanced non-small cell lung cancer patients: a phase II trialM Poudenx, P Y Bondiau, E Chamorey, et al.British Journal of Anaesthesia|July 20, 2012
Cardiopulmonary exercise testing predicts postoperative outcome in patients undergoing gastric bypass surgeryP J Hennis, P M Meale, R A Hurst, et al.Endocrine-Related Cancer|January 21, 2017
Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytologyPablo Valderrabano, Laila Khazai, Marino E Leon, et al.Antimicrobial Agents and Chemotherapy|January 27, 2004
Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2'-deoxy-2'-fluorocytidineLieven J Stuyver, Tamara R McBrayer, Tony Whitaker, et al.Nucleosides, Nucleotides & Nucleic Acids|October 27, 2005
Synthesis of N3,5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one and its 3'-deoxysugar analogue as potential anti-hepatitis C virus agentsPeiyuan Wang, Laurent Hollecker, Krzysztof W Pankiewicz, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 4, 2022
Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancerS Sumodhee, L Guo, L Bouhlel, et al.Pageof 57